Abstract
Background: Febrile neutropenia is one of the major acute side effects of intensive treatment in pediatric cancer, necessitating prompt initiation of empirical broad-spectrum antibiotics. Patients may be classified as low or high risk according some risk factors (duration of neutropenia, depth of neutropenia, type of cancer, state of disease, bone marrow involvement, type of treatment, additional health problems). Initial evaluation of the febrile neutropenic child should include the history of the child, a detailed physical examination, blood culture (peripheral and catheter), urinalysis and culture, cultures of lesions.
Result & Conclusion: The standard of care in febrile neutropenic children is that they should be hospitalized, especially if high risk, and should be treated urgently with intravenous wide spectrum empiric antibiotics, the spectrum covering P. Aeruginosa. Empiric treatment should be modified according to culture results and clinical situation. Other options for low risk patients are starting with intravenous treatment and continuing with per oral treatment or giving per oral antibiotic treatment from the beginning.
Keywords: Childhood cancer, febrile neutropenia, pediatrics, diagnosis, treatment, patients.
Current Pediatric Reviews
Title:Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment
Volume: 14 Issue: 3
Author(s): Rejin Kebudi*Hande Kizilocak
Affiliation:
- Cerrahpasa Faculty of Medicine, Pediatric Hematology-Oncology, Istanbul University, Istanbul,Turkey
Keywords: Childhood cancer, febrile neutropenia, pediatrics, diagnosis, treatment, patients.
Abstract: Background: Febrile neutropenia is one of the major acute side effects of intensive treatment in pediatric cancer, necessitating prompt initiation of empirical broad-spectrum antibiotics. Patients may be classified as low or high risk according some risk factors (duration of neutropenia, depth of neutropenia, type of cancer, state of disease, bone marrow involvement, type of treatment, additional health problems). Initial evaluation of the febrile neutropenic child should include the history of the child, a detailed physical examination, blood culture (peripheral and catheter), urinalysis and culture, cultures of lesions.
Result & Conclusion: The standard of care in febrile neutropenic children is that they should be hospitalized, especially if high risk, and should be treated urgently with intravenous wide spectrum empiric antibiotics, the spectrum covering P. Aeruginosa. Empiric treatment should be modified according to culture results and clinical situation. Other options for low risk patients are starting with intravenous treatment and continuing with per oral treatment or giving per oral antibiotic treatment from the beginning.
Export Options
About this article
Cite this article as:
Kebudi Rejin*, Kizilocak Hande, Febrile Neutropenia in Children with Cancer: Approach to Diagnosis and Treatment, Current Pediatric Reviews 2018; 14 (3) . https://dx.doi.org/10.2174/1573396314666180508121625
DOI https://dx.doi.org/10.2174/1573396314666180508121625 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter
Current Drug Metabolism The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Systemic Fungal Infections Caused by Candida Species: Epidemiology, Infection Process and Virulence Attributes
Current Drug Targets Serum Amyloid A and Its Potential Physiological / Pathological Functions - an Overview of Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Use of Antiepileptic Drugs in Paediatric Neurosurgical Conditions
Current Pharmaceutical Design Does Calprotectin Represent a Regulatory Factor in Host Defense or a Drug Target in Inflammatory Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of ncRNAs in Development, Diagnosis and Treatment of Human Cancer
Recent Patents on Anti-Cancer Drug Discovery FLT3 as a Therapeutic Target in Childhood Acute Leukemia
Current Drug Targets Editorial [Towards an Ecology of Collective Innovation: Human Variome Project (HVP), Rare Disease Consortium for Autosomal Loci (RaDiCAL) and Data-Enabled Life Sciences Alliance (DELSA)]
Current Pharmacogenomics and Personalized Medicine Epigenetic Effects of Environmental Chemicals on Reproductive Biology
Current Drug Targets Selective Cytotoxic Effects of 5-Trifluoromethoxy-<i>1H</i>-indole-2,3-dione 3-Thiosemicarbazone Derivatives on Lymphoid-originated Cells
Anti-Cancer Agents in Medicinal Chemistry Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination
Anti-Cancer Agents in Medicinal Chemistry Polyunsaturated Fatty Acids in Pregnancy and Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Vascular Calcification Revisited: A New Perspective for Phosphate Transport
Current Cardiology Reviews Mast Cell – Glia Dialogue in Chronic Pain and Neuropathic Pain: Blood-Brain Barrier Implications
CNS & Neurological Disorders - Drug Targets Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism